Given the excitement and anticipation of increasingly more promising prophylactic treatments and gene therapies, the 2nd Annual Hemophilia Drug Development Summit, once again unites leading pharma, biotech and academic KOLs working to translate and clinically develop longer acting and more efficacious therapies to overcome significant unmet medical need and hemophilia and other bleeding disorders.
Fuelled by current investment in the space and novel therapeutic strategies to improve current standard of care, the development of hemophilia therapeutics has been reinvigorated. Touted as an area of large unmet medical need but a well understood and defined disease profile, investment in this space is set to grow.
Join speakers from key companies such as Spark Therapeutics, BioMarin, Bayer, Sanofi, Novo Nordisk, Sangamo to meet the demand and treatment goals of patients, in a changing treatment paradigm.
Conference + 2 Workshops (Drug Developers): USD 3197.0,
Conference + 1 Workshop (Drug Developers): USD 2598.0,
Conference Only (Drug Developers): USD 2099.0,
Conference + 2 Workshops (Academics): USD 2497.0,
Conference + 1 Workshop (Academics): USD 1998.0,
Conference Only (Academics): USD 1499.0,
Conference + 2 Workshops (Standard): USD 3697.0,
Conference + 1 Workshop (Standard): USD 3298.0,
Conference Only (Standard): USD 2699.0
Speakers: Howard Levy, Chief Medical Officer, Catalyst Biosciences, H. Trent Spencer,President, Expression Therapeutics, Henry Mead, Director, Medical Communication and Education Strategy Hematology Medical Therapeutic Area Coagulation, CSL Behring, Aric Parnes, Associate Director, Boston Hemophilia Center, Crystal Watson, President and Chief Executive Officer, American Thrombosis and Hemostasis Network, Robert Peters, Rare Blood Disorders Therapeutic Area Head, Research, Sanofi Genzyme, Olubunmi, Afonja Medical Director, Bayer, Dean Falb, Chief Scientific Officer, LogicBio, Rosemarie Sellati, Director Development Sciences Patient Advocacy, Hematology, BioMarin Pharmaceutical, Jesper Haaning, Vice President, Global Research Project and Biopharm Management, Novo Nordisk, Michael Ero, Chief Executive Officer and President, Machaon Diagnostics, Nisha Jain, Executive Medical Director, Bioverativ, a Sanofi Company, Grant Blouse, Vice President, Translational Research, Catalyst Biosciences, Brendan Hayes, Director of External Affairs, National Hemophilia Foundation, Michelle Rice, Senior Vice President, External Affairs, National Hemophilia Foundation, Shauna Andersson, Clinical Research Director, Sanofi Genzyme, Edward Conner, Chief Medical Officer, Sangamo Therapeutics, Sander Van Deventer, Chief Scientific Officer, uniQure, Tessa Field, Patient Advocacy lead, Spark Therapeutics, Dawn Rotellini, Senior Vice President, Program Development, National Hemophilia Foundation